Annual Report 2024 Active Biotech AB (publ)
7 april, 11:00
Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2024 now is available for download at www.activebiotech.com.
The Annual Report will only be digitally distributed.
“In the past year, we made significant progress in our clinical projects. For 2025, we will focus on advancing the ongoing clinical studies in myelofibrosis. Additionally, we are awaiting results from both the clinical study with tasquinimod in multiple myeloma and the biodistribution study with laquinimod,” says Active Biotech CEO Helén Tuvesson.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies has been initiated. Also ongoing is a clinical Phase Ib/IIa study in multiple myeloma. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation is ongoing to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
This information is information that Active Biotech is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-07 11:00 CEST.
Attachments
Ämnen i artikeln
Annual Report 2024 Active Biotech AB (publ)
7 april, 11:00
Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2024 now is available for download at www.activebiotech.com.
The Annual Report will only be digitally distributed.
“In the past year, we made significant progress in our clinical projects. For 2025, we will focus on advancing the ongoing clinical studies in myelofibrosis. Additionally, we are awaiting results from both the clinical study with tasquinimod in multiple myeloma and the biodistribution study with laquinimod,” says Active Biotech CEO Helén Tuvesson.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies has been initiated. Also ongoing is a clinical Phase Ib/IIa study in multiple myeloma. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation is ongoing to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.
This information is information that Active Biotech is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-07 11:00 CEST.
Attachments
Ämnen i artikeln
Analys
-992x558.jpg&w=3840&q=75)
Danmarks nationaldag
-992x558.png&w=3840&q=75)
Fondernas placeringar
-992x558.jpg&w=3840&q=75)
Inflationen
-992x558.jpg&w=3840&q=75)
-992x558.jpg&w=3840&q=75)
Investmentbolag
Analys
Danmarks nationaldag
Fondernas placeringar
Inflationen
Investmentbolag
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
